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BACKGROUND: The purpose of this study was to investigate the overall survival (OS) of patients with advanced
ALK-positive nonsmall cell lung cancer (NSCLC) who were managed in the pre-ALK inhibitor era and to compare
their survival with that of a matched case cohort of ALK wild-type (WT) patients. METHODS: Data from 1166 patients
who had stage IIIB/IV NSCLC with nonsquamous histology were collected from the NSCLC database of Seoul
National University Hospital between 2003 and 2009. ALK fluorescence in situ hybridization (FISH) was used to ana-
lyze 262 patients who either had the WT epidermal growth factor receptor (EGFR) or were nonresponders to previ-
ous EGFR tyrosine kinase inhibitor (TKI) therapy. Overall survival (OS) was compared between 3 groups: 1) ALK-
positive patients, 2) EGFR mutation-positive patients, and 3) ALK-WT/EGFR-WT patients. Progression-free survival
(PFS) after first-line chemotherapy and EGFR TKIs also was analyzed. RESULTS: Twenty-three patients were ALK-
positive according to FISH analysis and did not receive ALK inhibitors during follow-up. The median OS for ALK-posi-
tive patients, EGFR mutation-positive patients, and WT/WT patients was 12.2 months, 29.6 months, and 19.3 months,
respectively (vs EGFR mutation-positive patients, P ¼ .001; vs WT/WT, P ¼ .127). The PFS after first-line chemotherapy
for the 3 groups was not different. However, the PFS for patients who received EGFR TKIs was shorter in ALK-posi-
tive patients compared with the other 2 groups (vs EGFR mutation-positive patients, P < .001; vs WT/WT, P < .021).
CONCLUSIONS: In the pre-ALK inhibitor era, ALK-positive patients experienced the shortest survival, although it did
not differ statistically from that of WT/WT patients. Although their responses to platinum-based chemotherapy were
not different from comparator groups, ALK-positive patients were even more resistant to EGFR TKI treatment than
WT/WT patients. Cancer 2012;118:3579-86. VC 2011 American Cancer Society.
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INTRODUCTION
It has become evident that nonsmall cell lung cancer (NSCLC) has distinct genetic alterations that are crucial for tumori-
genesis. These molecular changes, called driver mutations, allowed a new way to classify lung cancer into clinically relevant
subgroups.1-3 One of these groups is the echinioderm microtubule-associated protein-like 4 (EML4)-anaplastic lym-
phoma kinase (ALK) gene translocation EML4-ALK, which was identified in 2007.4,5 A small inversion within chromo-
some 2p results in the formation of a fusion gene comprising portions of the EML4 gene and the ALK gene.6 The product
of this fusion gene works as a driver for proliferation in lung cancer cells that harbor this translocation, demonstrating the
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phenomenon of oncogene addiction.7,8 Less than 3 years
after identification of the EML4-ALK translocation, a
phase 1 trial of crizotinib (PF-02341066; Pfizer, New
York, NY), an orally active ALK and MET dual inhibitor,
resulted in a significant response in patients who had the
EML4-ALK translocation. In a pretreated patient popula-
tion that generally has a 10% response rate to conven-
tional chemotherapy, treatment with crizotinib yielded an
overall response rate (ORR) of 55% and an estimated 6-
month progression-free survival (PFS) rate of 72%.9,10
Furthermore, the mechanism of resistance to crizotinib
was identified at the same time.11
In the center of this rapid advance of translational
research, there has been an early understanding of the clin-
ical and pathologic characteristics of patients with the
EML4-ALK translocation.12 Prevalence of the EML4-
ALK translocation in unselected patients with NSCLC
ranges from 3% to 5%.13-16 The EML4-ALK transloca-
tion is highly correlated with younger age and never-
smoking or light-smoking history.15,17 The pathologic
features of ALK-positive tumors also are distinct. Almost
all of them are adenocarcinomas; signet-ring cell histology
and acinar pattern were commonly identified.13,18-20
Recent studies have proposed using these clinicopatho-
logic characteristics as screening strategies to enrich for
the likelihood of ALK-positive tumors.3,21-23
The EML4-ALK translocation is now a clear positive
predictive marker of ALK-inhibitor therapy.9,24 However,
the prognostic value of ALK translocation is not fully
understood. Previous studies tried to analyze overall sur-
vival (OS) in patients with the EML4-ALK translocation,
but the clinical significance was in question because of
small numbers of events in enrolled patients and con-
founding from the administration of crizotinib in the
ALK-positive group.12,23 Therefore, we present the cur-
rent study, in which we compare ALK-positive patients
and matched ALK-WT patients who were treated in the
pre-ALK inhibitor era. Informed consent was obtained
from the patients and/or surrogates who participated in
this study. This protocol was reviewed and approved by
the Institutional Review Board (IRB) of Seoul National
University Hospital (IRB No. H-1008-035-326).
MATERIALS AND METHODS
Study Population
In total, 1166 patients who had stage IIIB/IV NSCLC
with nonsquamous histology were collected from the
NSCLC database of Seoul National University Hospital,
Seoul, Korea, between January 1, 2003 and August 31,
2009. To enrich for ALK-positive patients, we excluded
patients who harbored EGFR mutations, because the
EML4-ALK translocation is rarely coincident with EGFR
mutation.14,25 Among the patients with unknown EGFR
mutation status, we excluded patients who achieved an
objective response with gefitinib or erlotinib, using this as a
proxy for the likelihood of an EGFR mutation-positive
patient (Fig. 1).12 Patients who had insufficient tissue for
pathologic examination or whose tissue produced an incon-
clusive result in EML4-ALK fluorescence in situ hybridiza-
tion (FISH) also were excluded. Therefore, in total, 262
patients with examinable tissue were enrolled. Patients who
had received crizotinib were not included in the analysis.
Data Collection
The medical records of enrolled patients were reviewed to
collect demographic, clinical, and pathologic informa-
tion. We examined chemotherapeutic regimens,
responses, sites of metastases, and clinical outcomes. We
also recorded the EGFRmutation status of patients, which
had been determined using a direct sequencing method of
EGFR exons 18 to 21. Radiologic responses were eval-
uated according to version 1.0 of Response Evaluation
Criteria in Solid Tumors.26 OS was calculated from the
date metastatic disease was diagnosed to the date of death.
PFS was measured from the first day of chemotherapy
until radiologic or clinical disease progression.
Figure 1. This is a Consolidated Standards of Reporting Trials
(CONSORT) diagram illustrating the sample-enrichment
strategy. NSCLC indicates nonsmall cell lung carcinoma;
EGFR, epidermal growth factor receptor; ALK, anaplastic
lymphoma kinase.
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Pathologic Examination and Anaplastic
Lymphoma Kinase Testing
In total, 262 patients with testable formalin-fixed, paraf-
fin-embedded tissue were included in this study. Two
hundred six samples were biopsied by percutaneous tech-
nique, and 56 samples were surgically resected. All histo-
logic diagnoses were reviewed based on the latest World
Health Organization classification.27
ALK FISH analysis was performed using a dual-
color break-apart probe (Abbott Molecular, Abbott Park,
Ill), which hybridizes the 2p23 band (red signal) and the
ALK gene breakpoint (green signal). All procedures were
conducted according to the manufacturer’s instructions.
Three micron-sectioned, formalin-fixed, paraffin-embed-
ded tissues were deparaffinized, dehydrated, immersed in
0.2 N HCl, and incubated in 1 MNaSCN at 80C for 30
minutes. A pepsin solution was added to treated sections;
then, dual-probe hybridization for ALK was performed.
After application of the probe mixture, the slides were
treated with protease and then incubated in a humidified
atmosphere with HYBrite (Abbott Molecular) at 77C for
5 minutes for denaturation. Subsequently, the slides were
incubated at 37C for 16 hours for hybridization. Slides
were then immersed in 0.3% NP-40 (Abbott Molecular)/
0.4  saline sodium citrate (SSC) for 5 minutes at room
temperature, followed by 0.3%NP-40 of 0.4 SSC for 5
Table 1. Clinicopathologic Characteristics of Matched Cohorts











Age at diagnosis: MeanSD [median], y 47.411.4 [47.8] 49.66.0 [51.1] 50.98.1 [52.0] .383a .140
Sex
Men 9 (39.1) 17 (37) 19 (41.3) .861b .862
Women 14 (60.9) 29 (63) 27 (58.7)
Smoking history
Never or light-smoker 18 (78.3) 37 (80.4) 34 (73.9) .832 .693
Heavy smokerc 5 (21.7) 9 (19.6) 12 (26.1)
Pathology
Adenocarcinoma 16 (69.6) 41 (89.1) 37 (80.4) .043 .313
Nonsmall cell carcinoma, NOS 7 (30.4) 5 (10.9) 9 (19.6)
Stage
IIIB 0 (0) 1 (2.2) 0 (0) .476
IV 23 (100) 45 (97.8) 46 (100)
ECOG PS
0 7 (30.4) 12 (26.1) 12 (26.1)
1 13 (56.5) 26 (56.5) 27 (58.7)
2 3 (13.1) 7 (15.2) 6 (13)
3 0 (0) 1 (2.2) 1 (2.2)
4 0 (0) 0 (0) 0 (0)
First-line cytotoxic chemotherapy
Total 21 (91.3) 34 (73.9) 37 (80.4)
Gemcitabine/cisplatin 6 14 12
Paclitaxel/carboplatin 3 12 18
Others 12 8 7
EGFR TKI, any line
Total 17 (73.9) 42 (91.3) 27 (58.7)
Gefitinib 14 31 12
Erlotinib 3 11 15
Pemetrexed, any line 12 (52.2) 20 (43.5) 22 (47.8)
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor
receptor; NOS, not otherwise specified; SD, standard deviation; TKI, tyrosine kinase inhibitor.
a T test.
b Chi-square test.
c Heavy smoker means smoker who have smoked 10 pack years.
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minutes at 72C. For the counterstaining of nuclei, 4,6-
diamidino-2-phenylindole was used. FISH was regarded
as positive when break-apart signals or 50-deletions were
observed in >15% of 50 tumor cells. All specimens
from the FISH assay were examined by 1 trained patholo-
gist (H.S.P.) in a blinded manner.
Case-Case Matching and Statistical Analysis
To control for known prognostic variables in lung cancer
survival, each ALK-positive patient was matched to 2
EGFR mutation-positive patients and 2 WT/WT patients.
All patients in the matched cohort also were restricted to
nonsquamous histology. Matching variables were age at di-
agnosis, sex, disease stage, and smoking status. The cutoff
point for survival analysis was January 13, 2011.
Statistical analyses of categorical variables were per-
formed using Pearson chi-square tests or Fisher exact tests,
as appropriate. The t test was used to compare continuous
variables between groups. The median durations of OS
and PFS were calculated using the Kaplan-Meier method.
Comparisons between groups were done using the log-
rank test. Multivariate analysis was performed using a
Cox proportional hazards model. Two-sided P values <
.05 were considered statistically significant. All analyses
were performed using the PASW Statistics software pack-
age (version 18.0; SPSS Inc. Chicago, Ill).
RESULTS
Clinicopathologic Characteristics
Among 262 examined tumors, we identified 23 ALK-pos-
itive cases by FISH. One ALK-positive case was matched
to 2 EGFR mutation-positive patients and to 2 WT/WT
patients, as mentioned above (Table 1). All 3 groups
included patients with stage IV disease or recurrent
tumors except for 1 EGFR mutation-positive patient who
had stage IIIB disease. Consequently, a total of 115
patients (23 ALK-positive, 46 EGFR mutation-positive,
and 46 WT/WT patients) were included in the survival
analysis. On pathologic examination, the ALK-positive
group included more unspecified nonsmall cell carcino-
mas (30%) than the EGFR mutation-positive and WT/
WT groups (11% and 20%, respectively). Three ALK-
positive patients (13%) and 1 WT/WT patient (2%) had
signet ring cell carcinoma. In terms of metastatic site,
30% of both ALK-positive andWT/WT patients had cen-
tral nervous system (CNS) metastases proven in radiologic
or cerebrospinal fluid cytopathologic examinations during
treatment. However, EGFR mutation-positive patients
had a higher rate of CNSmetastasis (63%; P< .001) (Ta-
ble 2). Fewer liver metastases were observed in the WT/
WT group (P¼ .035).
Treatment Responses and Survival Analyses
We examined patient responses to and clinical outcomes
after chemotherapy and EGFR TKI treatment docu-
mented in the medical records (Tables 3 and 4). Among
115 patients, 92 patients (80%) received cytotoxic chem-
otherapy as first-line treatment. All of those patients
received a platinum-based doublet regimen, except for 2
patients who received gemcitabine/vinorelbine and doce-
taxel. Various doublet combinations were identified; the
most common regimen was paclitaxel/carboplatin, which
was received by 33 patients, followed by gemcitabine/cis-
platin (32 patients). Response rates to cytotoxic chemo-
therapy did not differ between the 3 groups (ALK-positive
patients, 27%; EGFR mutation-positive patients, 32%;
WT/WT patients, 35%). Although PFS for EGFR muta-
tion-positive patients (4.93 months) was longer than for
the other 2 groups (ALK-positive patients, 3.87 months;
WT/WT patients, 3.73 months) (Fig. 2), the difference
was not statistically significant (Table 4). In total, 73
Table 2. Distribution of Metastasis Sites
















Lung to lung 14 32 25 .322 16 33 33 .979
Liver 2 9 3 .136 8 16 6 .034
Adrenal 1 3 5 .581 5 4 6 .317
Bone 8 16 17 .972 12 23 26 .818
CNS 6 15 9 .363 7 31 14 <.001
Pleural effusion 4 8 6 .821 7 12 16 .663
Pericardial effusion 2 2 1 .457 3 3 4 .663
Abbreviations: ALK, anaplastic lymphoma kinase; CNS, central nervous system; EGFR, epidermal growth factor receptor; WT, wild type.
a Chi-square test.
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patients (63%) received subsequent cytotoxic chemother-
apy. The proportion of patients who received second-line
chemotherapy was well balanced between the groups
(ALK-positive patients, 70%; EGFR mutation-positive
patients, 59%; WT/WT patients, 65%,). Pemetrexed32
was the most commonly used agent as second-line therapy
Table 4. Results of Survival Analysis by Molecular Subtypes







No. of patients 23 46 46
Median OS (95% CI), mo 12.23 (6.60-17.87) 29.63 (24.73-34.53) 19.33 (9.11-29.55)
P vs ALK-positivea .001 .127
PFS after first-line chemotherapy
No. of patients 21 34 37
Median (95% CI), mo 3.87 (0.43-7.31) 4.93 (4.40-5.46) 3.73 (2.32-5.14)
P vs ALK-positivea .825 .474
PFS after EGFR TKI therapy
No. of patients 10b 42 27
Median (95% CI), mo 1.37 (1.07-1.67) 9.80 (4.94-14.66) 2.07 (0.15-3.99)
P vs ALK-positivea <.001 .037
Abbreviations: ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; OS, overall survival; PFS, progression-free
survival; TKI, tyrosine kinase inhibitor; WT, wild type.
a Log-rank P values were derived from a comparison of Kaplan-Meier estimates between patients who had ALK-positive tumors versus patients who had other
tumor types.
b Excludes patients who were enrolled because of a previous nonresponse to EGFR TKIs.

















Total 21 91.3 34 73.9 37 80.4
CR 0 0 0 0 0 0
PR 6 28.6 11 32.4 13 35.1
SD 8 38 12 35.3 15 40.5
PD 6 28.6 11 32.4 9 24.4
Unevaluable 1 4.8 0 0 0 0
Best response to
EGFR TKI
Total 10b 21.7 42 91.3 27 58.7
CR 0 0 3 7.1 0 0
PR 0 0 31 73.8 4 14.8
SD 2 20 6 14.3 7 25.9
PD 8 80 2 4.8 16 59.3
Unevaluable 0 0 0 0 0 0
Response rate, %
Chemotherapy 28.6 32.4 35.1 .857 .695
EGFR TKI 0 80.9 14.8 <.001 .096
Abbreviations: ALK, anaplastic lymphoma kinase; CR, complete response; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial
response; SD, stable disease; TKI, tyrosine kinase inhibitor; WT, wild type.
a Chi-square test.
bExcludes patients that were enrolled due to previous non-response to EGFR TKIs.
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followed by combined gemcitabine/vinorelbine18 and
docetaxel.8 PFS after second-line chemotherapy was did
not differ between the 3 groups (ALK-positive patients,
2.07 months; EGFR mutation-positive patients, 1.63
months; WT/WT patients, 2.93 months; P¼ .353).
Eighty-six patients were received an EGFR TKI.
Specifically, 57 patients received gefitinib, 29 patients
received erlotinib, and 4 patients received both agents.
For an appropriate comparison of PFS after EGFR TKI
treatment, we excluded ALK-positive patients who were
enrolled because of their nonresponses to EGFR TKI
treatment. Because all 9 ALK-positive patients already
were preselected on the basis of their nonresponse to
EGFR TKI, it was inappropriate to measure their PFS
because this was a selection criterion. If they had been
included, then it would have biased the group based on
nonresponse to TKI. The EGFR mutation-positive group
had a much higher response rate (81%) than the 2 other
groups (ALK-positive patients, 0%; WT/WT patients,
and 15%). ALK-positive patients who received an EGFR
TKI had rapid disease progression and did not respond to
EGFR TKI treatment. The median PFS for ALK-positive
patients (1.37 months) was shorter than that for the other
2 groups (EGFRmutation-positive patients, 9.80 months;
WT/WT patients, 2.07 months; P ¼ .037 vs WT/WT)
(Fig. 2).
The median OS of ALK-positive patients was 12.2
months compared with 29.6 months for EGFR mutation-
positive patients (P¼ .001) and 19.3 months for WT/WT
patients (P¼ .127). In a multivariate analysis that included
age, sex, stage, smoking status, and histology with a Cox-
proportional hazards model, the calculated hazard ratio
was 0.446 for EGFR mutation-positive patients and 0.631
forWT/WT patients. Other variables, including histology,
did not significantly affect OS. Finally, ALK-positive
patients had the shortest (albeit statistically nonsignificant)
median OS in the pre-ALK inhibitor era. They did not dif-
fer in their response to conventional cytotoxic chemother-
apy compared with ALK-WT patients. However, they were
more resistant to EGFR TKI treatment, even compared
withWT/WT patients.
DISCUSSION
In this study, we used FISH to identify an historic
cohort of ALK inhibitor-naive patients and examined
the possible prognostic role of the EML4-ALK trans-
location in the clinical outcomes of patients with
NSCLC. We demonstrated that the OS of ALK-posi-
tive patients did not differ statistically from their
WT/WT matched comparators, although their sur-
vival was numerically shorter. Shaw et al12 evaluated
survival outcomes in 17 patients with metastatic,
ALK-positive disease by determining PFS and OS. In
that study, ALK-positive patients had inferior clinical
outcomes compared with EGFR mutation-positive
patients, resembling the survival of WT/WT patients.
However, the number of events was small within the
ALK-positive patient group, the follow-up duration
was relatively short, and there were differences in age
Figure 2. Kaplan-Meier estimates of (Top) overall survival,
(Middle) progression-free survival (PFS) after first-line chem-
otherapy, (C) progression-free survival of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
among study patients. ALK indicates anaplastic lymphoma
kinase; mutþ, mutation positive; WT, wild type.
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and smoking status between comparator groups in
our study. Moreover, 7 of 17 ALK-positive patients
enrolled in the phase 1 crizotinib clinical trial,
which may have, as acknowledged by the author,
influenced the OS outcome of the study. To mini-
mize imbalances in potential prognostic clinicopath-
ologic characteristics, we performed a 2:1 case
matching of ALK-WT patients to ALK-positive
patients. This matching took into account age at di-
agnosis, sex, disease stage, and smoking status. The
follow-up period of our study was relatively long,
with a median follow-up of 26 months. In addition,
ALK inhibitor-related effects on survival fundamen-
tally were ruled out in our study. Although our
study had the limitations of a single-center, retro-
spective design and restricted statistical power
because of the small sample size, we carefully con-
trolled for confounding factors in our analyses in an
effort to present the comparative clinical course of
ALK-positive patients (treated without ALK inhibi-
tors) and ALK-WT patients.
The predictive role of the EML4-ALK translocation
in response to EGFR TKI therapy, which has been
described in several studies,12,22,28,29 was affirmed in the
current study. ALK-positive patients were more resistant
to EGFR TKI treatment, even compared with WT/WT
patients (P ¼ .037). This result also is in concordance
with the laboratory data published in 2008, which dem-
onstrated the resistance of an ALK-positive lung cancer
cell line to erlotinib.8 Recent studies repeatedly have
reported similar data on the resistance of ALK-positive
tumors to EGFR TKI, and a screening strategy for
ALK positivity has been proposed based on this
characteristic.12,22,23
The report by Shaw et al and a previous report from
our group also demonstrated an objective response rate to
conventional chemotherapy that was numerically smaller
in ALK-positive patients versus ALK-WT patients.12,22
However, this finding was not statistically significant in
those studies, either as a true result or as a function of the
limited sample size of ALK-positive patients in each study.
Larger sample sizes or pooled analyses may address this
issue more definitively.
Recent retrospective analyses have indicated that
ALK-positive patients were more sensitive to pemetrexed
compared with ALK-WT comparators.29,30 In the current
study, the percentage of pemetrexed exposure in any line
of ALK-positive, EGFR mutation-positive, and WT/WT
groups was 52%, 43%, and 48%, respectively. Despite
the relatively high use of pemetrexed in the ALK-positive
patients, this group had the shortest OS estimate.
ALK-positive patients had a lower rate of CNS me-
tastases (30%) during the follow-up period compared
with EGFR mutation-positive patients (63%), and this
rate was identical to that of the WT/WT patients (30%).
This result may have been caused by bias, because EGFR
mutation-positive patients had longer survival compared
with the other 2 groups. Six ALK-positive patients (26%),
15 EGFR mutation-positive patients (33%), and 9 WT/
WT patients (20%) had CNS metastases confirmed at
their initial staging workup. To compare the rate of CNS
metastasis in terms of a survival-related effect, a prospec-
tive survey would be helpful.
A significant portion of ALK-positive patients
(22%) identified in this study had a smoking history,
although 3 patients in the heavy-smoker group had 10
pack-year smoking history, which is a borderline value
for heavy smoker (defined as a smoking history of 10
pack-years). Similarly, a recent study by our group in a
different patient population also reported a large number
of smokers (31%) in the ALK-positive group.22 These
finding suggest that smoking status is not appropriate for
patient selection in ALK testing. Smoking history should
be approached and interpreted with caution, because it
can vary in different cultural and social contexts.
Although we excluded squamous cell histology in select-
ing our patients, our cohort had a significant portion of
nonsmall cell carcinoma, not otherwise specified (NOS).
We identified 7 ALK-positive patients with NOS histol-
ogy, including 3 who had an adenocarcinoma immuno-
phenotype that demonstrated expression of thyroid
transcription factor-1 and cytokeratin 7. Several previous
studies also have reported a small number of ALK-posi-
tive patients with nonadenocarcinoma histology.12,29-31
In addition, misclassification in histology can occur in
tumors that are difficult to specify; especially in patients
who have small specimens harvested by needle biopsy or
aspiration.32 Therefore, we should take care to restrict
ALK testing in patients with adenocarcinoma histology,
because we can miss a small number of ALK-positive
patients who have large cell, NOS, or other minor
histology.
In our current study, ALK positivity was suggestive
of a poor prognosis (although the finding not statistically
significant) and was predictive of poor EGFR TKI out-
comes. With the historically dismal survival observed
across the unselected NSCLC patient population, this
finding may signify an even greater unmet medical need
Survival of ALK-Positive Lung Cancer/Lee et al
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within the ALK-positive subset of patients with NSCLC,
and these patients are in need of effective therapy and do
not benefit from currently available targeted agents. With
the development of molecularly targeted therapy, such as
crizotinib, positive ALK status may prove to be a positive
predictive marker for ALK inhibitor therapy in the near
future.
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